Bruker Corporation (BMV:BRKR)
Mexico · Delayed Price · Currency is MXN | Market Cap | 141.98B +29.9% |
| Revenue (ttm) | 62.35B +0.4% |
| Net Income | -656.20M |
| EPS | -4.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 23.64 |
| Dividend | 3.67 (0.52%) |
| Ex-Dividend Date | Mar 23, 2026 |
| Volume | 1,720 |
| Open | 705.00 |
| Previous Close | 715.00 |
| Day's Range | 705.00 - 705.00 |
| 52-Week Range | 615.00 - 1,085.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Bruker
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron par... [Read more]
News
Bruker files automatic mixed securities shelf
16:17 EDT Bruker (BRKR) files automatic mixed securities shelf
Quanterix appoints Faessler as Chief Financial Officer
Quanterix (QTRX) announced the appointment of Jason Faessler as the Company’s new Chief Financial Officer, effective June 22. Faessler joins Quanterix from Bruker Corporation (BRKR), where he served a...
Bruker price target raised to $65 from $45 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on Bruker (BRKR) to $65 from $45 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Bruker Transcript: Jefferies Global Healthcare Conference 2026
Strong order growth in Q1 was led by semiconductor and international academic/government markets, while U.S. funding delays persist. Biopharma and security segments are robust outside the U.S., and cost-saving actions are driving margin improvements, with double-digit EPS growth expected through 2027.
Bruker showcases microbiology, infection diagnostics portfolio at ASM meeting
At ASM Microbe 2026, Bruker (BRKR) Corporation’s Microbiology & Infection Diagnostics division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnost...
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and ...
Jefferies semis analyst holds an analyst/industry conference call
Analysts Peterson, Stanton and Curtis, along with Mark Munch, President of Bruker (BRKR) Nano Group, discuss Bruker’s capabilities and exposure within the Semiconductor ecosystem, including Semiconduc...
Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fue...
Bruker price target raised to $65 from $49 at BofA
BofA raised the firm’s price target on Bruker (BRKR) to $65 from $49 and keeps a Buy rating on the shares. Diagnostic tools have rallied almost 10% in the last…
Wolfe assumes ‘really expensive’ Bruker with a Peer Perform
As previously reported, Wolfe Research downgraded Bruker (BRKR) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock. Bruker “has gotten really expensive…
Bruker assumed at Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Bruker (BRKR) to Peer Perform from Outperform with no price target as the analyst assumed coverage of the stock.
Bruker announces launch of timsMRMS system
At ASMS, Bruker (BRKR) Corporation announced the launch of the timsMRMS system. Frank Laukien, PhD, Bruker’s President and CEO, said: “Proteoforms are the fundamental unit of molecular disease. A sing...
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultr...
Bruker participates in a conference call with Jefferies
Life Science Tools & Diagnostics Analyst Peterson, along with Mark Munch, PhD, President of Bruker (BRKR) Nano Group discuss BRKR’s capabilities and positioning within the semi space on a conference…
Bruker announces commissioning of BioSpec 18 Tesla preclinical MRi
Bruker (BRKR) Corporation announced the commissioning of a novel BioSpec 18 Tesla preclinical MRI at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial ...
Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at...
Bruker Transcript: AGM 2026
The meeting confirmed a quorum, elected three directors through 2029, approved 2025 executive compensation, and ratified the appointment of independent auditors for 2026. Stockholders were invited to submit questions before adjournment.
Bruker price target raised to $45 from $40 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Hold rating on the shares.
Bruker price target raised to $45 from $43 at TD Cowen
TD Cowen raised the firm’s price target on Bruker (BRKR) to $45 from $43 and keeps a Hold rating on the shares. The firm updated its odel following Q1 results…
Bruker price target raised to $45 from $40 at UBS
UBS raised the firm’s price target on Bruker (BRKR) to $45 from $40 and keeps a Neutral rating on the shares.
Bruker price target raised to $53 from $45 at Barclays
Barclays analyst Luke Sergott raised the firm’s price target on Bruker (BRKR) to $53 from $45 and keeps an Overweight rating on the shares.
Bruker price target raised to $44 from $40 at Citi
Citi raised the firm’s price target on Bruker (BRKR) to $44 from $40 and keeps a Neutral rating on the shares.
Bruker reports Q1 adjusted EPS 31c, consensus 23c
Reports Q1 revenue $823.4M, consensus $795.67M. Frank H. Laukien, Bruker’s (BRKR) President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quart...
Bruker backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
06:35 EDT Bruker (BRKR) backs FY26 adjusted EPS view $2.10-$2.15, consensus $2.12
Bruker Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong bookings in AI-driven and security segments, despite U.S. academic and currency headwinds. Guidance for FY2026 is reaffirmed, with margin expansion and EPS growth driven by cost savings and innovation momentum.